Hebei Province has launched the four types of peripheral vascular interventional medical consumables alliance centralized procurement rules four quotation work, and the quotation has been completed recently.

4 types of interventional consumables, recently completed quotation
On January 16th, the Hebei Provincial Medical Drug and Equipment Centralized Procurement Center issued a notice on the implementation of the four pricing rules for the centralized and quantity based procurement of four types of medical consumables, including peripheral vascular intervention guidance pathways, in the inter provincial alliance. The notice also includes a list of companies that provide pricing for rule four, and requires them to complete the pricing for rule four. (Read the original text to obtain the list and original file)

According to the previously released procurement documents, Rule Four is as follows:
(1) After executing the selected rule three, enable the selected rule four, and the selected enterprise in rule four will be ranked after the selected enterprise in rule three.

(2) A non selected enterprise shall be determined as a selected enterprise if its confirmed price is not higher than 1.5 times (inclusive) the average selected price of all selected enterprises generated by the same product classification selection rules one, two, and three, and not higher than the original declared price of the enterprise. The maximum number of selected companies is not limited by the maximum number of shortlisted companies. The confirmed price shall not exceed the highest valid quoted price for the same product category.

The product types involved in the implementation of Rule 4 pricing in Hebei Province this time include 10 products, including peripheral vascular intervention guide pathway guide catheter, peripheral vascular intervention guide pathway guide sheath (group), intracranial balloon dilation catheter - integral exchange type, intracranial balloon dilation catheter - rapid exchange type, peripheral arterial balloon dilation catheter - guide wire diameter of 0.014 inches (rapid exchange type), peripheral arterial balloon dilation catheter - guide wire diameter of 0.014 inches (integral exchange type), peripheral arterial balloon dilation catheter - guide wire diameter of 0.018 inches, peripheral arterial balloon dilation catheter - guide wire diameter of 0.035 inches, peripheral arterial balloon dilation catheter (high-pressure balloon), and peripheral venous balloon dilation catheter. Classification: There are no blood flow guided dense mesh stent products listed.

According to the notice, the quotation time for Rule 4 is from 9:00 to 11:00 today (January 17th); Decryption time is from 11:00 to 12:00; The public announcement time for the declared price is 12:00.

In addition, there is also Rule 5 for this procurement: After implementing Rule 4 for the intended selection, if the agreed purchase quantity of the intended selected enterprise/medical device registration certificate is less than 30% of the agreed purchase quantity of the same product category, an additional intended selected enterprise/medical device registration certificate will be added through negotiation. According to the agreement of non selected enterprises/medical device registration certificate alliance regional medical institutions, negotiations will be conducted in descending order of procurement quantity. If an enterprise confirms that the price is not higher than the highest selected price generated by the same product classification selection rules one, two, three, and four, negotiations will be stopped, and the enterprise/medical device registration certificate will be determined as the selected one.

After the completion of Rule 5, the results of this centralized procurement will be officially announced.

Entering the field, accelerating centralized procurement
In 2024, there will be frequent large-scale actions in the field of centralized procurement.
From national procurement to local centralized procurement, various products such as peripheral vascular stents, peripheral vascular interventional microcatheters, micro guide wires, intracranial stents, thrombectomy stents, and blood flow guided dense mesh stents have all experienced a new round of price reductions. Among them, the lowest bid price for the national peripheral vascular stent reached 2280 yuan; The 24 province peripheral vascular intervention microcatheter and guidewire collection led by Gansu Province has achieved an average product reduction of 62.21%.

Overall, the focus of concentrated procurement in the field of intervention in 2024 will be on the two major tracks of nerves and periphery, both of which belong to the sub tracks previously dominated by foreign-funded enterprises. Under the comprehensive improvement and expansion of centralized procurement, domestic brands are gradually expanding their market share by leveraging their price advantages. According to a research report by Hua'an Securities, from 2020 to 2022, after the centralized procurement of nerve intervention spring coil consumables, the share of the four domestic giants rapidly increased from 3.85% to 17.00%.

However, compared to the first batch of national procurement of orthopedic consumables, in recent years, the participation of foreign-funded enterprises in high-value consumables field centralized procurement projects has significantly increased, and even showed stronger willingness to lower prices than some domestic enterprises. The fifth batch of national procurement of peripheral vascular stents category was selected by foreign-funded enterprises as the first place.

In the future, with the worsening of population aging and the increasing penetration rate of treatments for cardiovascular and cerebrovascular diseases, the amount of interventional consumables will continue to increase. In this category of high-end consumables, product quality, clinical recognition, and corporate services are all important factors affecting market share.
For domestic brands, price advantage is certainly important, but the competition for products ultimately depends on performance, service, and other aspects. Only by enhancing competitiveness in all aspects can we hope to further expand our market share. Under the trend of normalized centralized procurement, the industry pattern of intervening in consumables is bound to be rewritten, and domestic enterprises will also usher in new opportunities.

Conclusion
At the National Conference on Pharmaceutical Prices and Tendering Procurement held earlier, the key tasks for consumables procurement in 2025 were announced, which will continue to promote the improvement and expansion of centralized procurement of pharmaceutical consumables. The industry believes that this indicates that more varieties and ranges will be included in centralized procurement, especially high-value medical consumables, which will become the focus of centralized procurement. At the same time, with the trend of stricter management of consumables prices, the order of the consumables market will be further standardized, and the consumables market will become more pure and efficient in the future.

Source: https://news.yaozh.com/archive/44838.html